Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Abroad (travel likely)Recruiting

Conditions

Bladder Cancer · Metastatic Bladder Cancer · Unresectable Bladder Carcinoma · Urothelial Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Joaquim Bellmunt, MD, PhD) · Joaquim_bellmunt@dfci.harvard.edu · 617-632-2010
Contact: Principal Investigator (Joaquim Bellmunt, MD, PhD)

Study leads

Joaquim Bellmunt, MD, PhD
Principal Investigator
Dana-Farber Cancer Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE1

North Melbourne, Australia

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Bladder Cancer · Recurrent Bladder Cancer · Non-muscle Invasive Bladder Cancer (NMIBC)

Abroad (travel likely)Recruiting

Tampa, United States · Iowa City, United States

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Urothelial Carcinoma · Muscle-invasive Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Orange, United States

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Gainesville, United States